Development of an automated 7-day 96-well Caco-2 cell culture model

Pharmazie

Volumn 63, Issue 6, 2008, Pages 464-469

  Galkin, A ^a   Pakkanen, J ^b   Vuorela, P ^c  

^a Division of Pharmaceutical Biology   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c ÅBO AKADEMI UNIVERSITY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CARBON 14; DRUG; GLYCOPROTEIN P; HYDROCHLOROTHIAZIDE; KETOPROFEN; LUCIFER YELLOW; MANNITOL; METOPROLOL; NAPROXEN; RHODAMINE 123; VERAPAMIL;

ARTICLE; AUTOMATION; CELL DENSITY; CELL GROWTH; CELL STRAIN CACO 2; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG PENETRATION; ELECTRIC RESISTANCE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MICROSCOPY; MODEL;

ACTINS; ALGORITHMS; AUTOMATION; BIOLOGICAL MARKERS; CACO-2 CELLS; CELL COUNT; CELL MEMBRANE PERMEABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ELECTRIC IMPEDANCE; FLUORESCENT DYES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; ISOQUINOLINES; MICROSCOPY, CONFOCAL; P-GLYCOPROTEIN;

EID: 46849095431     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2008.7855     Document Type: Article

References (52)

1. Alsenz J, Steffen H, Alex R (1998) Active apical secretory efflux of the HTV protease inhibitors saquinavir and ritonavir in Caco-2 cell mono-layers. Pharm Res 15: 423-428.
2. Alsenz J, Haenel E (2003) Development of a 7-day, 96-well Caco-2 permeability assay with high-throughput direct UV compound analysis. Pharm Res 20: 1961-1969.
3. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39: 361-398.
4. Anderle P, Niederer E, Rubas W, Hilgendorf C, Spahn-Langguth H, Wun-derli-Allenspach H, Merkle HP, Langguth P (1998) P-Glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: the influence of cul-turing conditions and drug exposure on P-gp expression levels. J Pharm Sci 87: 757-762.
5. Artursson P, Palm K, Luthman K (2001) Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 46: 27-43.
6. Artursson P, Karlsson J, Ocklind G, Schipper N (1996) Studying transport processes in absorptive epithelia. In: Shaw AJ (ed.) Epithelial Cell Culture - A Practical Approach, Oxford University Press, pp. 111-133.
7. Bailey CA, Bryla P, Malick AW (1996) The use of the intestinal epithelial cell culture model, Caco-2, in pharmaceutical development. Adv Drug Deliv Rev 22: 85-103.
8. Balimane PV, Han YH, Chong S (2006) Current industrial practices of assessing permeability and P-glycoprotein interaction. AAPS J. 8: El-13.
9. Balimane PV, Patel K, Marino A, Chong S (2004) Utility of 96 well Caco-2 cell system for increased throughput of P-gp screening in drug discovery. Eur J Pharm Biopharm 58: 99-105.
10. Briske-Anderson MJ, Finley JW, Newman SM (1997) The influence of culture time and passage number on the morphological and physiological development of Caco-2 cells. Proc Soc Exp Biol Med 214: 248-257.
11. Choi JS, Jin MJ, Han, HK (2005) Role of monocarboxylic acid transporters in the cellular uptake of NSAIDs. J Pharm Pharmacol 57: 1185-1189.
12. Collett A, Tanianis-Hughes J, Warhurst G (2004) Rapid induction of P-glyco-protein expression by high permeability compounds in colonic cells in vitro: a possible source of transporter mediated drug interactions? Biochem Pharmacol 68: 783-790.
13. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR (1990) Expression of the multidrug resistance gene product (P-gly-coprotein) in human normal and tumor tissues. J Histochem Cytochem 38: 1277-1287.
14. Doppenschmitt S, Spahn-Langguth H, Regardh CG, Langguth P (1999) Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein. J Pharm Sci 88: 1067-1072.
15. Gan L, Moseley M, Khosla B, Augustijns P, Bradshaw T, Hendren R, Thakker D (1996) CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells. Drug Metab Dispos 24: 344-349.
16. Gao J, Murase O, Schowen RL, Aube J, Borchardt RT (2001) A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm Res 18: 171-176.
17. Garrigos M, Belehradek J Jr, Mir LM, Orlowski S (1993) Absence of cooperativity for MgATP and verapamil effects on the ATPase activity of P-glycoprotein containing membrane vesicles. Biochem Biophys Res Commun 196: 1034-1041.
18. Gombar VK, Silver IS, Zhao Z (2003) Role of ADME characteristics in drug discovery and their in silico evaluation: in silico screening of chemicals for their metabolic stability. Curr Top Med Chem 3: 1205-1225.
19. Hochman JH, Chiba M, Nishime J, Yamazaki M, Lin JH (2000) Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4. J Pharmacol Exp Ther 292: 310-318.
20. Hosoya KI, Kim KJ, Lee VH (1996) Age-dependent expression of P-glycoprotein gp170 in Caco-2 cell monolayers. Pharm Res 13: 885-890.
21. Hu M, Borchardt RT (1990) Mechanism of L-alpha-methyldopa transport through a monolayer of polarized human intestinal epithelial cells (Caco-2). Pharm Res 7: 1313-1319.
22. Hunter J, Hirst BH (1997) Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption. Adv Drug Deliv Rev 25: 129-157.
23. Hämalainen MD, Frostell-Karlsson A (2004) Predicting the intestinal absorption potential of hits and leads. Drug Discov Today: Technologies 1: 397-405.
24. Idriss HT, Hannun YA, Boulpaep E, Basavappa S (2000) Regulation of volume-activated chloride channels by P-glycoprotein: phosphorylau'on has the final say! J Physiol 524: 629-636.
25. Kreander K, Galkin A, Vuorela S, Tammela P, Laitinen L, Heinonen M, Vuorela P (2006) In-vitro mutagenic potential and effect on permeability of co-administered drugs across Caco-2 cell monolayers of Rubus idaeus and its fortified fractions. J Pharm Pharmacol 58: 1545-1552.
26. Laitinen LA, Tammela PS, Galkin A, Vuorela HJ, Marvola ML, Vuorela PM (2004) Effects of extracts of commonly consumed food supplements and food fractions on the permeability of drugs across Caco-2 cell monolayers. Pharm Res 21: 1904-1916.
27. Lennernäs H, Palm K, Fagerholm U, Artursson P (1996) Comparison between active and passive drug transport in human intestinal epithelial (Caco-2) cells in vitro and human jejunum in vivo. Int J Pharm 127: 103-107.
28. Mahadevan D, Shirahatti N (2005) Strategies for targeting the multidrug resistance-1 (MDRl)/P-gp transporter in human malignancies. Curr Cancer Drug Targets 5: 445-455.
29. Maimone MM, Merlie JP (1993) Interaction of the 43 kd postsynaptic protein with all subunits of the muscle nicotinic acetylcholine receptor. Neuron 11:53-66.
30. Marino AM, Yarde M, Patel H, Chong S, Balimane PV (2005) Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. Int J Pharm 297: 235-241.
31. Markowska M, Oberle R, Juzwin S, Hsu CP, Gryszkiewicz M, Streeter AJ (2001) Optimizing Caco-2 cell monolayers to increase throughput in drug intestinal absorption analysis. J Pharmacol Toxicol Methods 46: 51-55.
32. ™ Caco-2. 2002.
33. Nare B, Prichard RK, Georges E (1994) Characterization of rhodamine 123 binding to P-glycoprotein in human multidrug-resistant cells. Mol Pharmacol 45: 1145-1152.
34. Ogihara T, Kamiya M, Ozawa M, Fujita T, Yamamoto A, Yamashita S, Ohnishi S, Isomura Y (2006) What kinds of substrates show P-glycopro-tein-dependent intestinal absorption? Comparison of verapamil with vin-blastine. Drug Metab Pharmacokinet 21: 238-244.
35. Orlowski S, Mir LM, Belehradek J Jr, Garrigos M (1996) Effects of steroids and verapamil on P-glycoprotein ATPase activity: progesterone, desoxycorticosterone, corticosterone and verapamil are mutually non-exclusive modulators. Biochem J 317: 515-522.
36. Pascoe RJ, Masucci JA, Foley JP (2006) Investigation of vesicle electroki-netic chromatography as an in vitro assay for the estimation of intestinal permeability of pharmaceutical drag candidates. Electrophoresis 27: 793-804.
37. Perloff MD, Stormer E, von Moltke LL, Greenblatt DJ (2003) Rapid assessment of P-glycoprotein inhibition and induction in vitro. Pharm Res 20: 1177-1183.
38. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS (2001) Rational use of in vitro P-glycoprotein assays in drag discovery. J Pharmacol Exp Ther 299: 620-628.
39. Riihimaki L, Galkin A, Finel M, Heikura J, Valkonen K, Virtanen V, Laak-sonen R, Slotte JP, Vuorela P (2007) Transport properties of bovine and reindeer beta-lactoglobulin in the Caco-2 cell model. Int J Pharm 347: 1-8.
40. Schinkel AH (1997) The physiological function of drag-transporting P-gly-coproteins. Semin Cancer Biol 8: 161-170.
41. Siissalo S, Laitinen L, Koljonen M, Vellonen K, Kortejärvi H, Urtti A, Hirvonen J, Kaukonen AM (2007) Effect of cell differentiation and passage number on the expression of efflux proteins in wild type and vin-blastine-induced Caco-2 cell lines. Eur J Pharm Biopharm 67: 548-554.
42. Takanaga H, Tamai I, Tsuji A (1994) pH-dependent and carrier-mediated transport of salicylic acid across Caco-2 cells. J Pharm Pharmacol 46: 567-570.
43. Tamai I, Takanaga H, Maeda H, Sai Y, Ogihara T, Higashida H, Tsuji A (1995) Participation of a proton-cotransporter, MCT1, in the intestinal transport of monocarboxylic acids. Biochem Biophys Res Commun 214: 482-489.
44. Tammela P, Laitinen L, Galkin A, Wennberg T, Heczko R, Vuorela H, Slotte JP, Vuorela P (2004) Permeability characteristics and membrane affinity of flavonoids and alkyl gallates in Caco-2 cells and in phospho-lipid vesicles. Arch Biochem Biophys 425: 193-199.
45. Troutman MD, Thakker DR (2003) Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res 20: 1200-1209.
46. Tsuji A, Takanaga H, Tamai I, Terasaki T (1994) Transcellular transport of benzoic acid across Caco-2 cells by a pH-dependent and carrier-mediated transport mechanism. Pharm Res 11: 30-37.
47. Tsumo T, Iida H, Tsukagoshi S, Sakurai Y (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967-1972.
48. U.S. Department of Health and Human Services, Food and Drag Administration, Center for Drag Evaluation and Research (CDER) (2000) Guidance for industry, waiver of in vivo bioavailability and bioequiva-lence studies for immediate-release solid dosage forms based on a bio-pharmaceutics classification system, (http://www.fda.gov/cder/guidance/3618fnl.htm).
49. Watkins PB (1997) The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drag Deliv Rev 27: 161-170.
50. Yamashita S, Furubayashi T, Kataoka M, Sakane T, Sezaki H, Tokuda H (2000) Optimized conditions for prediction of intestinal drag permeability using Caco-2 cells. Eur J Pharm Sci 10: 195-204.
51. Yamashita S, Konishi K, Yamazaki Y, Taki Y, Sakane T, Sezaki H, Furuyama Y (2002) New and better protocols for a short-term Caco-2 cell culture system. J Pharm Sci 91: 669-679.
52. Yu H, Cook TJ, Sinko PJ (1997) Evidence for diminished functional expression of intestinal transporters in Caco-2 cell monolayers at high passages. Pharm Res 14: 757-762.